Down syndrome and Alzheimer disease: response to donepezil.
Arch Neurol
; 59(7): 1133-6, 2002 Jul.
Article
em En
| MEDLINE
| ID: mdl-12117361
ABSTRACT
BACKGROUND:
Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors.OBJECTIVE:
To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment.DESIGN:
A nonrandomized controlled trial using donepezil in a pilot study format.SETTING:
Academic medical center. PATIENTS Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects. INTERVENTION Oral administration of donepezil for a 5-month period. PRIMARY OUTCOMEMEASURE:
The Down Syndrome Dementia Scale.RESULTS:
Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03).CONCLUSIONS:
Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Inibidores da Colinesterase
/
Síndrome de Down
/
Nootrópicos
/
Doença de Alzheimer
/
Indanos
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2002
Tipo de documento:
Article